Home  >  Health Check  >  Covid-19 plasma therapy trial results ‘disappointing’
Health Check
Covid-19 plasma therapy trial results ‘disappointing’
Health Check
Oct 28, 2020

For months now, many people hospitalised with Covid-19 have been given convalescent plasma – donated blood serum from people who’ve already had the illness. The hope has been that transfusing donated antibodies against the coronavirus will help to prevent deaths and serious illness. Convalescent plasma therapy received a high profile boost in the USA in August when the Trump administration announced emergency use authorisation for the treatment, despite the lack of robust evidence for its efficacy against the coronavirus. Now the results of the first completed randomised clinical trial of the therapy have been published in the British Medical Journal. The findings are not particularly encouraging. In this Indian study, there was no difference in the death rate or the progression from moderate to severe disease between patients given the therapy and those receiving only standard care. Claudia Hammond talks to Dr Aparna Mukherjee of the India Council of Medical Research and the BBC’s medicine and science correspondent James Gallagher about the prospects now for convalescent plasma therapy.

Health Check also asks whether vaccines against other diseases might provide some protection against the coronavirus, and features a report from California where a lot of mental health counselling has gone online or on the phone since the pandemic took hold. Reporter Alison Van Diggelen asks people with mental health problems and their therapists how they feel about the loss of face-to-face sessions.

Presenter: Claudia Hammond Producer: Andrew Luck-Baker

(Picture: An Iraqi phlebotomist holds a bag of plasma donated by a recovered Covid-19 patient. Photo credit: Asaad Niazi/AFP/Getty Images.)

More Episodes

Jun 24, 2026
Lack of evidence most IVF ‘add-ons’ improve fertility

Many people with infertility use in vitro fertilisation (IVF), however the probability of having a baby following IVF is only approximately 30-40% per cycle and decreases significantly with age. It can be a lengthy and expensive process. Providers sometimes offer ‘add-ons’, additional treatments that they claim could help patients conceive, which are themselves also usually expensive. In Australia, New Zealand and the United Kingdom more than 70% of patients pay for at least one of these add-ons. A new review published in The Lancet Obstetrics, Gynaecology, & Women’s Health journal has found that evidence on the benefits of these add-on treatments is unclear. Claudia Hammond speaks to Dr Sarah Lensen, Senior Research Fellow in the Department of Obstetrics, Gynaecology and Newborn Health at the University of Melbourne.

Joining Claudia from Ghana is genito-urinary consultant and HIV expert, Vanessa Apea. Claudia and Vanessa discuss a draft African Charter on Family, Sovereignty and Values, which claims that comprehensive sex education, as well as a range of sexual and reproductive health rights, are a threat to African families from foreign ideologies.

They also discuss a report from the Office of Inspector General of US Agency for International Development (USAID) which reveals that President Donald Trump’s administration has spent hundreds of thousands of dollars in storage and transportation costs for $9.7 million worth of contraceptives that are being stored in Belgium rather than distributed to the various low-income countries they were intended for. Many of the withheld contraceptives are now expired or unusable due to their removal from temperature-controlled storage.

We also hear from Health Check reporter Jane Chambers in the Chilean city of Valdivia, where wetlands are part of everyday life—and increasingly, part of people’s health. And we hear how faecal-microbiome transplants could improve the efficacy of some antidepressants in patients with major depressive disorder.

Presenter: Claudia Hammond Producers: Jonathan Blackwell & Georgia Christie


26min 29sec



Covid-19 plasma therapy trial results ‘disappointing’

--:--
--:--